Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease

NCT07280299 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease

Interventions

DRUG: Low Dose GT-02287
DRUG: High Dose GT-02287
DRUG: Placebo

Sponsor

Gain Therapeutics, Inc.